MedTrace Logo

BIOMARGIN European, Ambispective Cohort of Adult and Paediatric Renal Transplant Patients

NCT02832661 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2016-07-14

No results posted yet for this study

Summary

Biomargin is a European research program aimed at evaluating the diagnostic performance of biomarkers with respect to renal graft injuries, as well as their prognostic performance with respect to 3-year and 5-year graft outcomes.

Nucleic acids, proteins and metabolites previously identified as candidate biomarkers of individual kidney graft lesions will be determined systematically in urine and blood samples collected in patients from the time of transplantation onwards, as well as in the graft tissue when biopsies are required for medical causes or performed systematically in the investigation centres. Their diagnostic and prognostic performance will be checked against histological reading of the biopsies and evolution of the graft function over time.

Conditions

  • Kidney Transplantation

Sponsors & Collaborators

  • Hannover Medical School

    collaborator OTHER

  • KU Leuven

    collaborator OTHER

  • Hôpital Necker-Enfants Malades

    collaborator OTHER

  • Hospital Purpan

    collaborator OTHER

  • University Hospital, Limoges

    lead OTHER

Eligibility

Min Age
1 Year
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-03-31
Primary Completion
2020-03-31
Completion
2020-03-31

Countries

  • Belgium
  • France
  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02832661 on ClinicalTrials.gov